Chinook Therapeutics Inc KDNY:NASDAQ

Last Price$12.59NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change-1.16(8.44%)
Bid (Size)$12.60 (4)
Ask (Size)$12.61 (26)
Day Low / High$12.49 - 13.59
Volume327.4 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/18/2022

 

Chinook Therapeutics Inc ( NASDAQ )

Price: $12.59
Change: -1.16 (8.44%)
Volume: 327.4 K
4:00PM ET 5/18/2022
 
 

Phibro Animal Health Corp ( NASDAQ )

Price: $18.67
Change: -0.03 (0.16%)
Volume: 117.3 K
4:00PM ET 5/18/2022
 
 

Mirum Pharmaceuticals Inc ( NASDAQ )

Price: $22.95
Change: -1.07 (4.45%)
Volume: 148.3 K
4:00PM ET 5/18/2022
 
 

Catalyst Pharmaceuticals Inc ( NASDAQ )

Price: $6.82
Change: -0.35 (4.88%)
Volume: 1.1 M
4:00PM ET 5/18/2022
 
 

Evolus Inc ( NASDAQ )

Price: $12.33
Change: -1.61 (11.55%)
Volume: 697.6 K
4:00PM ET 5/18/2022
 

Read more news Recent News

--Wedbush Lifts Price Target on Chinook Therapeutics to $30 From $29, Keeps Outperform Rating
7:13AM ET 5/13/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Chinook Therapeutics Initiates Phase 1 Trial of CHK-336 in Healthy Volunteers
9:07AM ET 4/12/2022 MT Newswires

Chinook Therapeutics (KDNY) said Tuesday that dosing has been initiated in a phase 1 clinical trial evaluating CHK-336 in adult healthy volunteers. ...

Wedbush Adjusts Chinook Therapeutics' Price Target to $29 From $28, Noting Expense Trajectory, Decline in Projected Share Count; Outperform Rating Kept
6:27AM ET 3/18/2022 MT Newswires

Chinook Therapeutics (KDNY) has an average rating of buy and price targets ranging from $25 to $40, according to analysts polled by Capital IQ. (MT...

Chinook Therapeutics Swings to Q4 Profit as Revenue Increases
4:55AM ET 3/18/2022 MT Newswires

Chinook Therapeutics (KDNY) reported Q4 earnings Thursday of $0.14 per diluted share, compared with a loss of $1.24 per share a year earlier. Two analysts...

View all Commentary and Analysis

Chinook Therapeutics (KDNY) Investor Presentation - Slideshow
2:51PM ET 5/06/2022 Seeking Alpha

Tracking Baker Brothers Portfolio - Q4 2021 Update
10:10PM ET 3/30/2022 Seeking Alpha

Tracking Baker Brothers Portfolio - Q3 2021 Update
10:32PM ET 1/04/2022 Seeking Alpha

Week In Review: BeiGene Raises $3.5 Billion In Shanghai STAR Board IPO
3:37PM ET 12/05/2021 Seeking Alpha

Company Profile

Business DescriptionChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. View company web site for more details
Address400 Fairview Avenue North
Seattle, Washington 98109
Phone+1.206.485.7241
Number of Employees152
Recent SEC Filing05/12/202210-Q
Chairman, President & Chief Executive OfficerEric L. Dobmeier
Chief Operating OfficerTom Frohlich
Chief Financial OfficerEric Hands Claude Bjerkholt
Chief Scientific OfficerAndrew King

Company Highlights

Price Open$13.39
Previous Close$12.59
52 Week Range$10.48 - 19.85
Market Capitalization$694.7 M
Shares Outstanding55.2 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.10
Beta vs. S&P 500N/A
Revenue$15.1 M
Net Profit Margin-199.39%
Return on Equity-31.18%

Analyst Ratings as of 05/11/2022

Buy
7
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset